English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

It has been reported that younger patients with non-small cell lung cancer (NSCLC) tend to have a better prognosis. Yet, few studies have focused on the clinicopathological characteristics and prognosis of young small cell lung cancer (SCLC), especially for patients with age &lt; 50. In our study, we used Surveillance, Epidemiology, and End Results (SEER) population-based data and identified 16503 patients with SCLC including 711 patients aged &lt; 50, 3338 patients aged 50-59, 5937 patients aged 60-69, 4649 patients aged 70-79 and 1868 patients aged ≥ 80 between 2010 and 2013. The Kaplan-Meier methods was used to develop the survival curve, and the results showed that the SCLC patients with aged &lt; 50 tended to a better over survival (OS) and cancer specific survival (CSS) (all, P &lt; 0.001). In addition, Cox regression model was used to analyze survival prognosis factors and perform subgroup analysis. The results showed that age was an independent prognostic factor for CSS (P &lt; 0.001). Importantly, we found that for the patients with AJCC stage III subgroup, the age &lt; 50 had apparent CSS benefit compared with any other age group (all, P &lt; 0.01). Interestingly, for the patients with no surgery, radiation and no radiation subgroup, the age &lt; 50 had no apparent CSS benefit only compared with age 50-59 (all, P &gt; 0.05). In conclusion, our study demonstrated that the SCLC patients with aged &lt; 50 tended had a better survival benefit, especially for patients with AJCC stage III.

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III